Green Tea Component Has Potential To Inhibit HIV Infection
07 February 2009
A chemical that occurs naturally in green tea appears to prevent HIV-1 (the virus associated with AIDS) from infecting cells in the immune system and could prove a valuable part of treatment for the disease, said researchers from Baylor College of Medicine and Texas Children's Hospital.In previous studies Dr. Christina Nance and Dr. William T. Shearer had demonstrated that epigallocatechin gallate or EGCG, found in green tea, blocks the ability of HIV-1 to attach to a cellular entry molecule called gp120. This inhibits the virus' ability to infect cells.
"Now we have shown that EGCG can inhibit infection not only in a specific strain of HIV but in multiple subtypes and strains," Nance said. "This is paramount from a global aspect. Most initial studies with HIV in the Americas are based on subtype B." However, most of the world is infected with other strains.
"Previously, we had shown how it worked. This is definitive proof that the compound inhibits actual HIV infection in lymphocytes or T-cells.
In this study, they exposed immune cells from the blood of people who did not have HIV/AIDS to the virus in the laboratory. They then incubated these HIV infected immune cells with EGCG. They found that the compound blocked the ability of the virus to infect other cells.
Molecular components of the compound called pryogallol and galloyl appear to be responsible for the prevention of the gp120 protein from attaching to the CD4 molecule found on T-cells, a key component of the immune systems.
This effect occurs at concentrations that would be non-toxic to people.
"Thus, EGCG may represent a potential low-cost inhibitor of global HIV infection that could be used at least as adjunctive anti HIV therapy."
Previous drugs developed to block the entry of HIV into cells proved ineffective because the virus mutated.
"Once HIV is exposed to drug, it finds a way around it," said Nance. She said she hopes that EGCG, derived from a natural product, will be less likely to generate such mutations. Currently, she is doing tests to determine whether EGCG will generate such resistant mutations.
That preliminary work could help clear the way for early patient studies, she said. BCM has received a grant from the National Institutes of Health to being a phase 1 trial to study the safety of the compound in HIV infected people.
Related Articles
 Circumcision, which substantially lowers HIV risk in men, also dramatically changes the bacterial communities of the penis, according to a study.
And these bacterial
|
 According to a study, the virus that causes AIDS may undergo changes in the genital tract that make HIV-1 in semen different than what it is in the blood.
Worldwide
|
|
According to a paper in the journal AIDS Research and Human Retroviruses , HIV disease tends to progress at a faster rate in infected individuals who consume two or more alcoholic drinks a
|
|
Scientists have identified a set of naturally occurring antibodies that can block one of the key ways the AIDS virus gains entry into certain blood cells.
|
Estimated number of people in the world living with HIV AIDS in 2008.
A total of 50,670 new HIV cases were reported in Russia in 2008, bringing the total number of registered HIV cases since
|
References:
1. Christina Nance, William T. Shearer. Baylor College of Medicine.
2. Image by td stevenson.
